Fairvalue-Calculator Fairvalue-Calculator
EN DE

High Tech Pharm Co (106190) Fair Value & Analysis

Healthcare · KR · Market cap 151B KRW

Price13,530 KRW
Fair Value12,074 KRW
Upside-10.8%
Quality95/100
Evidence: High Range 9,051 KRW – 15,097 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

High Tech Pharm Co (106190) currently trades at 13,530 KRW, while our model-based Fair Value estimate is 12,074 KRW — implying the stock looks roughly 10.8% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is High Tech Pharm Co (106190) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 12,074 KRW versus a price of 13,530 KRW — about −11% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 106190?
Our 21-model fair value for High Tech Pharm Co is 12,074 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 13,530 KRW.
What is the quality score of 106190?
High Tech Pharm Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.